These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 8392995)

  • 1. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
    Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.
    Thomson CJ; Amyes SG
    Epidemiol Infect; 1993 Feb; 110(1):117-25. PubMed ID: 8432315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OHIO-1 beta-lactamase resistant to mechanism-based inactivators.
    Bonomo RA; Currie-McCumber C; Shlaes DM
    FEMS Microbiol Lett; 1992 Apr; 71(1):79-82. PubMed ID: 1320587
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRC-1: emergence of a clavulanic acid-resistant TEM beta-lactamase in a clinical strain.
    Thomson CJ; Amyes SG
    FEMS Microbiol Lett; 1992 Mar; 70(2):113-7. PubMed ID: 1316862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
    London N; Thomson CJ; Amyes SG; Stobberingh E
    FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA; Baquero F; Pérez-Díaz JC; Martínez JL
    J Antimicrob Chemother; 1991 May; 27(5):569-75. PubMed ID: 1653204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
    Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
    J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
    Simonet M; Moittie D; Philippon A; Descamps P; Veron M
    J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of beta-lactamase inhibitors with various beta-lactamases.
    Cullmann W
    Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmid encoded beta-lactamases resistant to inhibition by clavulanic acid produced by calf faecal coliforms.
    Hunter JE; Corkill JE; McLennan AG; Fletcher JN; Hart CA
    Res Vet Sci; 1993 Nov; 55(3):367-70. PubMed ID: 8284502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
    Corkill JE; Hart CA; McLennan AG; Aspinall S
    J Gen Microbiol; 1991 Jun; 137(6):1425-9. PubMed ID: 1655952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
    Moosdeen F; Keeble J; Williams JD
    Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
    Caniça MM; Caroff N; Barthélémy M; Labia R; Krishnamoorthy R; Paul G; Dupret JM
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1323-8. PubMed ID: 9624468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.